Iovance Biotherapeutics, Inc.
NASDAQ:IOVABiotechnology
Healthcare
$7.48 -0.89%
-$0.04 today
- Market cap
- $3.46B
- Beta
- 0.70
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.85
52W Low $1.66High $5.63
Volume 6.99M
Average 14.09M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$302.41M
FY 2025 · Annual
Investing Cash Flow
$47.50M
FY 2025 · Annual
Financing Cash Flow
$300.77M
FY 2025 · Annual
-23.0% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (342.25M) | (395.89M) | (444.04M) | (372.18M) | (390.98M) |
| Depreciation & Amortization | 13.98M | 21.14M | 33.13M | 43.61M | 47.32M |
| Deferred Income Tax | 0 | 0 | (3.48M) | (2.83M) | (2.07M) |
| Stock-Based Compensation | 69.77M | 84.02M | 62.63M | 109.63M | 61.58M |
| Change in Working Capital | 24.55M | (2.89M) | (6.52M) | (122.56M) | (24.27M) |
| Accounts Receivables | 0 | 0 | (149K) | (69.19M) | (13.11M) |
| Inventory | 0 | 0 | (10.12M) | (39.92M) | (14.21M) |
| Accounts Payables | 6.98M | 5.88M | 4.83M | (7.84M) | (6.66M) |
| Other Working Capital | 17.58M | (8.78M) | (1.08M) | (5.61M) | 9.71M |
| Other Non-Cash Items | 6.01M | 871K | (3.54M) | (8.65M) | 6.01M |
| Operating Cash Flow | (227.94M) | (292.76M) | (361.82M) | (352.98M) | (302.41M) |
| Capital Expenditures | (37.57M) | (20.43M) | (22.29M) | (11.07M) | (33.84M) |
| Acquisitions (Net) | (37.71M) | (276.88M) | (212.63M) | (52.57M) | 0 |
| Purchases of Investments | (725.21M) | (245.82M) | (205.9M) | (460.77M) | (318.67M) |
| Sales of Investments | 762.91M | 522.7M | 285.58M | 428M | 400M |
| Other Investing Activities | 37.71M | 276.88M | 0 | 0 | 0 |
| Investing Cash Flow | 132K | 256.46M | (155.24M) | (96.41M) | 47.5M |
| Debt Repayment | 1M | 0 | 0 | 0 | 0 |
| Common Stock Issued | 203.16M | 189.5M | 463.28M | 397.3M | 306.31M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 35.11M | 648K | (322K) | (6.64M) | (7.06M) |
| Financing Cash Flow | 239.27M | 190.15M | 462.96M | 390.66M | 300.77M |
| Effect of Forex Changes | 0 | 0 | (2.74M) | (541K) | 1.52M |
| Net Change in Cash | 11.46M | 153.85M | (56.84M) | (59.27M) | 47.38M |
| Free Cash Flow | (265.52M) | (313.18M) | (384.11M) | (364.05M) | (336.24M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$391.0M
+ D&A$47.3M
+ Stock-Based Comp$61.6M
- Deferred Tax-$2.1M
- Working Capital-$24.3M
+ Other Non-Cash$6.0M
= Operating Cash Flow-$302.4M
- Capex-$33.8M
= Free Cash Flow-$336.2M
Analysis
FY2025 free cash flow is -$336.2M. FCF conversion is 86.0% of net income. Operating cash flow was -$302.4M, with capex of -$33.8M. The largest bridge item is Stock-Based Comp at $61.6M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 |
Does IOVA generate free cash flow?
Iovance Biotherapeutics, Inc. (IOVA) generated -$336.24M of free cash flow in fiscal 2025.
How much operating cash flow does IOVA produce?
Operating cash flow was -$302.41M, before capital expenditures of $33.84M.
Continue the stock analysis
Jump to another research area for this company.